Electronic health records have a big role to play in improving hospitals' medication reconciliation, a new study finds, but challenges related to data quality, technology and workflow remain. [See ...
A clinic visit, hospital admission, or transition in care often begins with medication reconciliation. Developed to provide safer, more coordinated, and better-quality care, medication reconciliation ...
The authors propose statewide programs that would expand the Prescription Drug Monitoring Program for all medications-not just opiates-in order to reduce outpatient medication errors. In the ...
The authors used aggregate pharmacy claims data available within a primary care electronic health record to identify a high rate of medication discrepancies. ABSTRACTObjectives: Methods for efficient ...
Background: Hospital discharge is an interface of care when patients are at a high risk of medication discrepancies as they transition from hospital to home. These discrepancies are important, as they ...
Proper medication reconciliation can help prevent adverse drug events by identifying exactly what medications a patient was taking before coming to the hospital and confirming appropriate medication ...
The elderly and chronically ill patients are typically challenged with many drugs and complicated dosing regimens, often leading to medication errors. Medication errors are one of the most common ...
FORT LEE, Va. (May 29, 2014) -- What is Medication Reconciliation? It's is a process to prevent medication errors. One might ask, how is this handled at Kenner Army Health Clinic? Kenner has a process ...
An effective hospital discharge process created by Cleveland Clinic is pivotal in the handoff of patients to postacute-care providers. Hospital discharge is a complex process involving the primary ...
Researchers implemented a medication reconciliation interview to improve accuracy of and adherence to medication reconciliation. DENVER — Implementation of a standardized medication reconciliation ...
Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors From December 2022 to January 2025, one MRT ...
Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors Accurate medication reconciliation is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results